<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03487549</url>
  </required_header>
  <id_info>
    <org_study_id>VP-102-105</org_study_id>
    <nct_id>NCT03487549</nct_id>
  </id_info>
  <brief_title>Cantharidin and Occlusion in Verruca Epithelium</brief_title>
  <acronym>COVE-1</acronym>
  <official_title>A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verrica Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instat Consulting, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paidion Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioClinica, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALMAC Clinical Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Verrica Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1&#xD;
      [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and&#xD;
      tolerability of VP-102 treatment in subjects with common warts. This study has two Cohorts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first Cohort (Cohort 1) utilizes a treatment interval of at least 14 days between&#xD;
      treatments with longer treatment intervals being allowed depending on a specific patient's&#xD;
      clinical response.Twenty Subjects (2 years and older) are targeted completing End of Study&#xD;
      (EOS) visit in Cohort 1.&#xD;
&#xD;
      The second Cohort (Cohort 2) utilizes a treatment interval of 21 days between treatments.&#xD;
      Paring of lesions is allowed. Approximately 35 subjects (12 years and older) will be enrolled&#xD;
      in Cohort 2. Up to 4 sites will participate in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Actual">July 15, 2019</completion_date>
  <primary_completion_date type="Actual">May 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This study has 2 cohorts. Cohort 1 of the study enrolled 21 subjects and has completed all subject related study activities. Analysis is to be conducted at Day 84. Cohort 2 will utilize 4 sites with an enrollment of approximately 35 subjects. The primary analysis will be conducted at Day 84 with an additional period of follow up out to Day 147.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84)</measure>
    <time_frame>Treatment Visit Day 1 (Baseline) compared to Day 84 (EOS) Visit.</time_frame>
    <description>Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOS Visit (Day 84).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84)</measure>
    <time_frame>Compare Treatment Visit 1 (Baseline) to EOT Visit (Day 84)</time_frame>
    <description>Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOS Visit (Day 84)</measure>
    <time_frame>Change in the number of warts compared at Baseline (Visit 1) to the End of Study Visit (Day 84).</time_frame>
    <description>Cohort 1: Change from baseline in the number of treatable warts (baseline and new) at the EOS Visit (Day 84).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit (Day 84).</measure>
    <time_frame>Baseline (Visit 1) to End of Treatment Visit (Day 84).</time_frame>
    <description>Cohort 1: Assessing the percent change from Baseline in the number of treatable warts (Baseline and new) at the EOT visit (Day 84).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study</measure>
    <time_frame>Baseline, Day 14, 28, 42 and 84 (EOS)</time_frame>
    <description>Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Visit 2, Visit 3, Visit 4 and over the duration of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit Day 84)</measure>
    <time_frame>Baseline, Day 84 (EOS)</time_frame>
    <description>Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at the EOT Visit Day 84).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Change From Baseline in the Percent of Treatable Warts (Baseline and New) at the EOT Visit (Day 84)</measure>
    <time_frame>Baseline (Visit 1) to End of Treatment Visit (Day 84).</time_frame>
    <description>Cohort 2: Change from baseline in the percent of treatable warts (baseline and new) at the EOT Visit (Day 84).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study</measure>
    <time_frame>Baseline, Day 21, 42, 63, and 84 (EOS), 105, 126, and 147</time_frame>
    <description>Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts, (baseline and new), at Visit 2, Visit 3, Visit 4 and over the duration of the study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cohort 1:Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study.</measure>
    <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
    <description>Cohort 1: Percent change from baseline in the number of treatable warts (Baseline and new) from Baseline at Visit 2, Visit 3, Visit 4 and over the duration of the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and the EOS Visit</measure>
    <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
    <description>Cohort 1: Change from baseline in the number of treatable warts (baseline and new) at Visit 2, Visit 3, Visit 4 and the EOS Visit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1: Proportion of Subjects Exhibiting ≥ 50% Clearance of All Treatable Warts (Baseline and New) at the EOS Visit as Compared to Baseline</measure>
    <time_frame>Compare Treatment Visit 1 (Baseline) to End of Study (Day 84).</time_frame>
    <description>Cohort 1: Proportion of subjects exhibiting ≥ 50% clearance of all treatable warts (baseline and new) at the EOS visit as compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1-Proportion of Subjects Who Respond to Treatment Defined by a ≥ 50% Reduction in Total Wart Area at EOS Compared to Baseline</measure>
    <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
    <description>Cohort 1-Proportion of subjects who respond to treatment defined by a ≥ 50% reduction in total wart area at EOS compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 1-Proportion of Subjects Exhibiting Reduction of at Least 1 Treatable Wart From Baseline at Visit 2, Visit 3, Visit 4 and at the EOS Visit (Day 84)</measure>
    <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
    <description>Cohort 1-Proportion of subjects exhibiting reduction of at least 1 treatable wart from baseline at Visit 2, Visit 3, Visit 4 and at the EOS Visit (Day 84).</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 2: Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over Duration of the Study.</measure>
    <time_frame>Baseline to Treatment Visits 2 (Day 21), 3 (Day 42), 4 (Day 63) through the End of Treatment (Day 84).</time_frame>
    <description>Cohort 2: Intent to Treat population Cohort 2-Percent reduction of all treatable warts (baseline and new) from baseline at Visit 2, Visit 3, Visit 4 and over duration of the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4 and the EOT Visit (Day 84)</measure>
    <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
    <description>Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4 and the EOT Visit (Day 84).</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 2: Proportion of Subjects Exhibiting ≥ 50 % Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84) as Compared to Baseline</measure>
    <time_frame>Baseline to Day 84 (EOT)</time_frame>
    <description>Cohort 2: Proportion of subjects exhibiting ≥ 50 % clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84) as compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 2: Proportion of Subjects Who Respond to Treatment Defined by a ≥ 50% Reduction in Total Wart Area at EOT Compared to Baseline</measure>
    <time_frame>Baseline to EOT (Day 84)</time_frame>
    <description>Cohort 2: Proportion of subjects who respond to treatment defined by a ≥ 50% reduction in total wart area at EOT compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 2: Proportion of Subjects Exhibiting Reduction of at Least 1 Treatable Wart From Baseline at Visit 2, Visit 3, Visit 4 and at the EOT Visit (Day 84)</measure>
    <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
    <description>Cohort 2: Proportion of subjects exhibiting reduction of at least 1 treatable wart from baseline at Visit 2, Visit 3, Visit 4 and at the EOT Visit (Day 84).</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Follow-up Visits on Day 105, Day 126 and Day 147</measure>
    <time_frame>Treatment Visit 1 (Baseline) to each follow-up visit Day 105, Day 126 and Day 147.</time_frame>
    <description>Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at follow-up visits on Day 105, Day 126 and Day 147.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 2: Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Follow-up Visits on Day 105, Day 126 and Day 147</measure>
    <time_frame>Baseline to follow-up visits on Day 105, Day 126 and Day 147</time_frame>
    <description>Cohort 2: Percent reduction of all treatable warts (baseline and new) from baseline at follow-up visits on Day 105, Day 126 and Day 147.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Follow-up Visits on Day 105, Day 126 and Day 147</measure>
    <time_frame>baseline to Day 105, Day 126 and Day 147</time_frame>
    <description>Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at follow-up visits on Day 105, Day 126 and Day 147.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Common Wart</condition>
  <condition>Warts Hand</condition>
  <condition>Warts</condition>
  <condition>Papillomavirus Infections</condition>
  <condition>DNA Virus Infections</condition>
  <condition>Skin Diseases, Viral</condition>
  <condition>Skin Diseases, Infectious</condition>
  <condition>Skin Diseases</condition>
  <condition>Virus Diseases</condition>
  <condition>Tumor Virus Infections</condition>
  <condition>Verruca Vulgaris</condition>
  <condition>Verruca</condition>
  <arm_group>
    <arm_group_label>VP-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>VP-102 Cantharidin topical film forming solution</intervention_name>
    <description>VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.</description>
    <arm_group_label>VP-102</arm_group_label>
    <other_name>VP-102-Cantharidin, film forming solution, VP-102 - Cohort 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>VP-102 Cantharidin, topical film forming solution</intervention_name>
    <description>VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.</description>
    <arm_group_label>VP-102</arm_group_label>
    <other_name>VP-102 Cantharidin, film forming solution, VP-102 - Cohort 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be healthy, immunocompetent males or females at least 2 years of age and older for&#xD;
             Cohort 1 and 12 years of age and older for Cohort 2.&#xD;
&#xD;
          2. Present with 1-6 common warts (verruca vulgaris) located anywhere on the body except&#xD;
             for the following prohibited areas: the eye area (including eyelids), lips, oral&#xD;
             cavity, nasal cavity, inside of the ears, palms of the hands, volar surface of the&#xD;
             fingers or toes, under the finger nails (near and on the sides of the nails is allowed&#xD;
             for Cohort 1, but warts near and on the sides of the nail (e.g., periungual) are not&#xD;
             allowed in Cohort 2), soles of the feet, or the anogenital area. (Warts within 10 mm&#xD;
             of a mucosal surface should not be treated).&#xD;
&#xD;
          3. Have warts that are ≤10 mm in diameter and ≤3 mm in height. (Subjects with warts that&#xD;
             are adjacent, touching or clustered may be included so long as the combined diameter&#xD;
             in the longest direction does not exceed 10 mm. Individual lesions that are adjacent,&#xD;
             touching or clustered should be counted as distinct lesions for the purposes of&#xD;
             tracking, inclusion and clearance)(subjects in Cohort 2 can be pared, when necessary&#xD;
             and appropriate, prior to evaluating height eligibility) .&#xD;
&#xD;
          4. Have warts that have been present for at least 4 weeks at the time of the baseline&#xD;
             visit.&#xD;
&#xD;
          5. Consent to having all warts treated (the physician must also be willing to treat all&#xD;
             warts initially present).&#xD;
&#xD;
          6. Be otherwise medically healthy with no clinically significant medical history,&#xD;
             physical examination or vital signs as determined by the investigator.&#xD;
&#xD;
          7. Be free of any systemic or dermatologic disorder, which, in the opinion of the&#xD;
             investigator, will interfere with the study results or increase the risk of Aes.&#xD;
&#xD;
          8. Refrain from swimming, bathing or prolonged immersion in water or any liquids until&#xD;
             the Study drug is removed.&#xD;
&#xD;
          9. Have the ability, or have a guardian with the ability, to follow study instructions&#xD;
             and be likely to complete all study requirements.&#xD;
&#xD;
         10. Agree to use no wart-removing product (prescription or over-the-counter [OTC]) other&#xD;
             than the Study drug during the course of the study.&#xD;
&#xD;
         11. Provide written informed consent or assent in a manner approved by the institutional&#xD;
             review board (IRB) and/or have a parent/guardian provide written informed consent as&#xD;
             evidenced by the signature on an IRB approved assent/consent form.&#xD;
&#xD;
         12. Provide written authorization for use and disclosure of protected health information.&#xD;
&#xD;
         13. If participating in the optional photographic portion of the study, agree to allow&#xD;
             photographs of warts to be taken at each Treatment Visit by the research team and&#xD;
             agree to share photos taken at home with the research team via text, email or&#xD;
             in-person upload.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Are unable to cooperate with the requirements or visits of the study, as determined by&#xD;
             the investigator.&#xD;
&#xD;
          2. Are systemically immunosuppressed or have required, or will require, systemic&#xD;
             immunosuppressive or immunomodulatory medication (including oral or parenteral&#xD;
             corticosteroids) within 30 days prior to enrollment or during the course of the study.&#xD;
             (Routine use of inhaled or intranasal corticosteroids during the study is allowed)&#xD;
&#xD;
          3. Have any chronic or acute medical condition that, in the opinion of the investigator,&#xD;
             may interfere with the study results or place the subject at undue risk. (e.g., human&#xD;
             immunodeficiency virus, systemic lupus erythematosus, viral hepatitis, uncontrolled&#xD;
             diabetes). NOTE: Immunizations and flu shots may be administered throughout the study,&#xD;
             but not within 5 days before or after treatment.&#xD;
&#xD;
          4. Have more than 6 common warts at baseline.&#xD;
&#xD;
          5. Present with any verruca plana, mosaiform, filiform, subungual (under the nail),&#xD;
             genital or anal warts. In Cohort 2, subjects with periungual warts are also excluded.&#xD;
&#xD;
          6. Have any warts present at baseline in an anatomic location that the subject,&#xD;
             parent/guardian or the physician is unwilling to treat or are located in an area that&#xD;
             cannot be easily occluded with tape.&#xD;
&#xD;
          7. Have had any previous treatment of common warts including, but not limited to, the use&#xD;
             of cantharidin, antivirals, retinoids, salicylic acid, lactic acid, hydrogen peroxide,&#xD;
             candida antigen, diphencyprone, dinitrochlorobenzene, sandalwood oil, thuja oil,&#xD;
             squaric acid dibutyl ester, povidone iodine, nitric oxide, curettage or freezing of&#xD;
             warts in the past 14 days. In addition, these treatments or any other over-the-counter&#xD;
             wart treatment should not be implemented during the course of the study.&#xD;
&#xD;
          8. Have been treated within 14 days with a product that contains cantharidin (topical or&#xD;
             homeopathic preparations) for any reason prior to screening.&#xD;
&#xD;
          9. Have received another investigational product as part of a clinical trial within 30&#xD;
             days prior to the first application of the Study drug.&#xD;
&#xD;
         10. Currently have or have a history of epidermodysplasia verruciformis.&#xD;
&#xD;
         11. Have a history of illness or any dermatologic disorder, which, in the opinion of the&#xD;
             investigator, will interfere with accurate assessment of the warts or increase the&#xD;
             risk of adverse events.&#xD;
&#xD;
         12. Have an active malignancy or are undergoing treatment for any malignancy.&#xD;
&#xD;
         13. Have a history or presence of clinically significant medical, psychiatric, or&#xD;
             emotional condition or abnormality that, in the opinion of the investigator, would&#xD;
             compromise the safety of the subject or the quality of the data.&#xD;
&#xD;
         14. Have a history or presence of hypersensitivity or an idiosyncratic reaction to the&#xD;
             Study drug or related compounds, or drug product excipients (acetone, ethyl alcohol,&#xD;
             nitrocellulose, hydroxypropyl cellulose, castor oil, camphor, gentian violet, and&#xD;
             denatonium benzoate).&#xD;
&#xD;
         15. Have a condition or situation that may interfere significantly with the subject's&#xD;
             participation in the study (e.g., subjects who required hospitalization in the 2&#xD;
             months prior to screening for an acute or chronic condition including alcohol or drug&#xD;
             abuse), at the discretion of the investigator.&#xD;
&#xD;
         16. Are sexually active or may become sexually active and are unwilling to practice&#xD;
             responsible birth control methods. (e.g., combination of condoms and foam, birth&#xD;
             control pills, intrauterine device, patch, shot and vaginal ring, etc.). Withdrawal is&#xD;
             not an acceptable method of birth control. Females that have reached menarche must&#xD;
             have a negative urine pregnancy test at each visit prior to treatment with Study drug.&#xD;
&#xD;
         17. Are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Nasir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cohort 1: Wake Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Guenthner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cohort 2: Indiana Clinical Trials Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cohort 2: Applied Research Center of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cohort 2: Solutions Through Advanced Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cohort 2: The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cohort 2: Clarkston Skin Research</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cohort 1-Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2018</study_first_posted>
  <results_first_submitted>June 7, 2021</results_first_submitted>
  <results_first_submitted_qc>August 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2021</results_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Warts</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>DNA Virus Infections</mesh_term>
    <mesh_term>Tumor Virus Infections</mesh_term>
    <mesh_term>Skin Diseases, Viral</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Cantharidin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03487549/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03487549/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The protocol was originally designed with one- cohort, it was later modified to include two cohorts. Subjects in Cohort 1 completed enrollment prior to beginning enrollment of new Subjects into Cohort 2.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed. Subjects were 2 years and older.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. Utilized a treatment interval of at least 21 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. Paring of lesions was allowed. Subjects were 12 years and older.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study participants enrolled into Cohort 1 were not included in Cohort 2. New subjects were enrolled into Cohort 2.</population>
      <group_list>
        <group group_id="B1">
          <title>VP-102 - Cohort 1</title>
          <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed.&#xD;
VP-102 Cantharidin topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 14 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
        </group>
        <group group_id="B2">
          <title>VP-102 - Cohort 2</title>
          <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of at least 21 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.86" spread="21.247"/>
                    <measurement group_id="B2" value="37.66" spread="16.435"/>
                    <measurement group_id="B3" value="37.75" spread="18.212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline wart count</title>
          <units>Baseline wart count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.19" spread="1.569"/>
                    <measurement group_id="B2" value="1.65" spread="1.098"/>
                    <measurement group_id="B3" value="1.85" spread="1.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84)</title>
        <description>Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOS Visit (Day 84).</description>
        <time_frame>Treatment Visit Day 1 (Baseline) compared to Day 84 (EOS) Visit.</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed. Subjects were 2 years and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84)</title>
          <description>Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOS Visit (Day 84).</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84)</title>
        <description>Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84).</description>
        <time_frame>Compare Treatment Visit 1 (Baseline) to EOT Visit (Day 84)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84)</title>
          <description>Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84).</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOS Visit (Day 84)</title>
        <description>Cohort 1: Change from baseline in the number of treatable warts (baseline and new) at the EOS Visit (Day 84).</description>
        <time_frame>Change in the number of warts compared at Baseline (Visit 1) to the End of Study Visit (Day 84).</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed. Subjects were 2 years and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOS Visit (Day 84)</title>
          <description>Cohort 1: Change from baseline in the number of treatable warts (baseline and new) at the EOS Visit (Day 84).</description>
          <population>ITT Population</population>
          <units>Number of warts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" spread="1.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="1.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1: Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit (Day 84).</title>
        <description>Cohort 1: Assessing the percent change from Baseline in the number of treatable warts (Baseline and new) at the EOT visit (Day 84).</description>
        <time_frame>Baseline (Visit 1) to End of Treatment Visit (Day 84).</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed. Subjects were 2 years and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Percent Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit (Day 84).</title>
          <description>Cohort 1: Assessing the percent change from Baseline in the number of treatable warts (Baseline and new) at the EOT visit (Day 84).</description>
          <population>ITT Population</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.19" spread="42.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study</title>
        <description>Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Visit 2, Visit 3, Visit 4 and over the duration of the study.</description>
        <time_frame>Baseline, Day 14, 28, 42 and 84 (EOS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed. Subjects were 2 years and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study</title>
          <description>Cohort 1: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at Visit 2, Visit 3, Visit 4 and over the duration of the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Clearance Reported at any Visit?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 84 (EOS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit Day 84)</title>
        <description>Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at the EOT Visit Day 84).</description>
        <time_frame>Baseline, Day 84 (EOS)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at the EOT Visit Day 84)</title>
          <description>Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at the EOT Visit Day 84).</description>
          <population>ITT Population</population>
          <units>change in wart count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="1.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2: Change From Baseline in the Percent of Treatable Warts (Baseline and New) at the EOT Visit (Day 84)</title>
        <description>Cohort 2: Change from baseline in the percent of treatable warts (baseline and new) at the EOT Visit (Day 84).</description>
        <time_frame>Baseline (Visit 1) to End of Treatment Visit (Day 84).</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Change From Baseline in the Percent of Treatable Warts (Baseline and New) at the EOT Visit (Day 84)</title>
          <description>Cohort 2: Change from baseline in the percent of treatable warts (baseline and new) at the EOT Visit (Day 84).</description>
          <population>ITT Population</population>
          <units>percentage of change in wart count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.79" spread="55.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study</title>
        <description>Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts, (baseline and new), at Visit 2, Visit 3, Visit 4 and over the duration of the study.</description>
        <time_frame>Baseline, Day 21, 42, 63, and 84 (EOS), 105, 126, and 147</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts, (Baseline and New), at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study</title>
          <description>Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts, (baseline and new), at Visit 2, Visit 3, Visit 4 and over the duration of the study.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Clearance Reported at Day 21 (Treatment Visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 42 (Treatment Visit 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 63 (Treatment Visit 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 84 (EOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 105</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 147</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 1:Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study.</title>
        <description>Cohort 1: Percent change from baseline in the number of treatable warts (Baseline and new) from Baseline at Visit 2, Visit 3, Visit 4 and over the duration of the study.</description>
        <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed. Subjects were 2 years and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1:Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over the Duration of the Study.</title>
          <description>Cohort 1: Percent change from baseline in the number of treatable warts (Baseline and new) from Baseline at Visit 2, Visit 3, Visit 4 and over the duration of the study.</description>
          <population>ITT Population</population>
          <units>Percent change in number of warts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Visit 2 Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="3.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 3 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.30" spread="30.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 4 Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.29" spread="42.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.19" spread="42.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and the EOS Visit</title>
        <description>Cohort 1: Change from baseline in the number of treatable warts (baseline and new) at Visit 2, Visit 3, Visit 4 and the EOS Visit.</description>
        <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed. Subjects were 2 years and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Visit 2, Visit 3, Visit 4 and the EOS Visit</title>
          <description>Cohort 1: Change from baseline in the number of treatable warts (baseline and new) at Visit 2, Visit 3, Visit 4 and the EOS Visit.</description>
          <population>ITT Population</population>
          <units>change in wart count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="1.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="1.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 1: Proportion of Subjects Exhibiting ≥ 50% Clearance of All Treatable Warts (Baseline and New) at the EOS Visit as Compared to Baseline</title>
        <description>Cohort 1: Proportion of subjects exhibiting ≥ 50% clearance of all treatable warts (baseline and new) at the EOS visit as compared to baseline.</description>
        <time_frame>Compare Treatment Visit 1 (Baseline) to End of Study (Day 84).</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed. Subjects were 2 years and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Proportion of Subjects Exhibiting ≥ 50% Clearance of All Treatable Warts (Baseline and New) at the EOS Visit as Compared to Baseline</title>
          <description>Cohort 1: Proportion of subjects exhibiting ≥ 50% clearance of all treatable warts (baseline and new) at the EOS visit as compared to baseline.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 1-Proportion of Subjects Who Respond to Treatment Defined by a ≥ 50% Reduction in Total Wart Area at EOS Compared to Baseline</title>
        <description>Cohort 1-Proportion of subjects who respond to treatment defined by a ≥ 50% reduction in total wart area at EOS compared to baseline.</description>
        <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed. Subjects were 2 years and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1-Proportion of Subjects Who Respond to Treatment Defined by a ≥ 50% Reduction in Total Wart Area at EOS Compared to Baseline</title>
          <description>Cohort 1-Proportion of subjects who respond to treatment defined by a ≥ 50% reduction in total wart area at EOS compared to baseline.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 1-Proportion of Subjects Exhibiting Reduction of at Least 1 Treatable Wart From Baseline at Visit 2, Visit 3, Visit 4 and at the EOS Visit (Day 84)</title>
        <description>Cohort 1-Proportion of subjects exhibiting reduction of at least 1 treatable wart from baseline at Visit 2, Visit 3, Visit 4 and at the EOS Visit (Day 84).</description>
        <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed. Subjects were 2 years and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1-Proportion of Subjects Exhibiting Reduction of at Least 1 Treatable Wart From Baseline at Visit 2, Visit 3, Visit 4 and at the EOS Visit (Day 84)</title>
          <description>Cohort 1-Proportion of subjects exhibiting reduction of at least 1 treatable wart from baseline at Visit 2, Visit 3, Visit 4 and at the EOS Visit (Day 84).</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reduction of &gt;= 1 Wart from Baseline at any visit?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wart Reduction &gt;= 1 Reported at Day 14 (Visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wart Reduction &gt;= 1 Reported at Day 28 (Visit 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wart Reduction &gt;= 1 Reported at Day 42 (Visit 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wart Reduction &gt;= 1 Reported at Day 84 (EOS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 2: Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over Duration of the Study.</title>
        <description>Cohort 2: Intent to Treat population Cohort 2-Percent reduction of all treatable warts (baseline and new) from baseline at Visit 2, Visit 3, Visit 4 and over duration of the study.</description>
        <time_frame>Baseline to Treatment Visits 2 (Day 21), 3 (Day 42), 4 (Day 63) through the End of Treatment (Day 84).</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Visit 2, Visit 3, Visit 4 and Over Duration of the Study.</title>
          <description>Cohort 2: Intent to Treat population Cohort 2-Percent reduction of all treatable warts (baseline and new) from baseline at Visit 2, Visit 3, Visit 4 and over duration of the study.</description>
          <population>ITT population</population>
          <units>percentage of change in wart count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 21 (Treatment Visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.18" spread="37.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Treatment Visit 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.85" spread="41.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 (Treatment Visit 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.12" spread="53.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (End of Treatment Visit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.79" spread="55.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4 and the EOT Visit (Day 84)</title>
        <description>Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4 and the EOT Visit (Day 84).</description>
        <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4 and the EOT Visit (Day 84)</title>
          <description>Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at Treatment Visit 2, Treatment Visit 3, Treatment Visit 4 and the EOT Visit (Day 84).</description>
          <population>ITT Population</population>
          <units>change in wart count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 21 (Treatment Visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Treatment Visit 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 (Treatment Visit 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (End of Treatment Visit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="1.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 2: Proportion of Subjects Exhibiting ≥ 50 % Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84) as Compared to Baseline</title>
        <description>Cohort 2: Proportion of subjects exhibiting ≥ 50 % clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84) as compared to baseline.</description>
        <time_frame>Baseline to Day 84 (EOT)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Proportion of Subjects Exhibiting ≥ 50 % Clearance of All Treatable Warts (Baseline and New) at the EOT Visit (Day 84) as Compared to Baseline</title>
          <description>Cohort 2: Proportion of subjects exhibiting ≥ 50 % clearance of all treatable warts (baseline and new) at the EOT Visit (Day 84) as compared to baseline.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 2: Proportion of Subjects Who Respond to Treatment Defined by a ≥ 50% Reduction in Total Wart Area at EOT Compared to Baseline</title>
        <description>Cohort 2: Proportion of subjects who respond to treatment defined by a ≥ 50% reduction in total wart area at EOT compared to baseline.</description>
        <time_frame>Baseline to EOT (Day 84)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Proportion of Subjects Who Respond to Treatment Defined by a ≥ 50% Reduction in Total Wart Area at EOT Compared to Baseline</title>
          <description>Cohort 2: Proportion of subjects who respond to treatment defined by a ≥ 50% reduction in total wart area at EOT compared to baseline.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 2: Proportion of Subjects Exhibiting Reduction of at Least 1 Treatable Wart From Baseline at Visit 2, Visit 3, Visit 4 and at the EOT Visit (Day 84)</title>
        <description>Cohort 2: Proportion of subjects exhibiting reduction of at least 1 treatable wart from baseline at Visit 2, Visit 3, Visit 4 and at the EOT Visit (Day 84).</description>
        <time_frame>Baseline, Day 14, 28, 42, and 84 (EOS)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Proportion of Subjects Exhibiting Reduction of at Least 1 Treatable Wart From Baseline at Visit 2, Visit 3, Visit 4 and at the EOT Visit (Day 84)</title>
          <description>Cohort 2: Proportion of subjects exhibiting reduction of at least 1 treatable wart from baseline at Visit 2, Visit 3, Visit 4 and at the EOT Visit (Day 84).</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 21 (Treatment Visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Treatment Visit 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 (Treatment Visit 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (End of Treatment Visit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Follow-up Visits on Day 105, Day 126 and Day 147</title>
        <description>Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at follow-up visits on Day 105, Day 126 and Day 147.</description>
        <time_frame>Treatment Visit 1 (Baseline) to each follow-up visit Day 105, Day 126 and Day 147.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at Follow-up Visits on Day 105, Day 126 and Day 147</title>
          <description>Cohort 2: Proportion of subjects exhibiting complete clearance of all treatable warts (baseline and new) at follow-up visits on Day 105, Day 126 and Day 147.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Clearance Reported at Day 105</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clearance Reported at Day 147</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 2: Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Follow-up Visits on Day 105, Day 126 and Day 147</title>
        <description>Cohort 2: Percent reduction of all treatable warts (baseline and new) from baseline at follow-up visits on Day 105, Day 126 and Day 147.</description>
        <time_frame>Baseline to follow-up visits on Day 105, Day 126 and Day 147</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Percent Reduction of All Treatable Warts (Baseline and New) From Baseline at Follow-up Visits on Day 105, Day 126 and Day 147</title>
          <description>Cohort 2: Percent reduction of all treatable warts (baseline and new) from baseline at follow-up visits on Day 105, Day 126 and Day 147.</description>
          <population>ITT Population</population>
          <units>percentage change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 105</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.91" spread="54.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.61" spread="52.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 147</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.61" spread="52.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Follow-up Visits on Day 105, Day 126 and Day 147</title>
        <description>Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at follow-up visits on Day 105, Day 126 and Day 147.</description>
        <time_frame>baseline to Day 105, Day 126 and Day 147</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>VP-102 - Cohort 2</title>
            <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.&#xD;
Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed.&#xD;
VP-102 Cantharidin, topical film forming solution: VP-102 Cantharidin topical film forming solution. Treatment interval of at least 21 days between treatments.&#xD;
VP-102 Applicator: The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2: Change From Baseline in the Number of Treatable Warts (Baseline and New) at Follow-up Visits on Day 105, Day 126 and Day 147</title>
          <description>Cohort 2: Change from baseline in the number of treatable warts (baseline and new) at follow-up visits on Day 105, Day 126 and Day 147.</description>
          <population>ITT Population</population>
          <units>change in wart count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 105</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 147</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Cohort 1: Day of first treatment until Day 84 Cohort 2: Day of first treatment until Day 84, 105, 126, 147</time_frame>
      <desc>Treatment Emergent Adverse Events (TEAEs) are defined as those AEx that occurred after dosing and those existing AEs that worsened during the study. If it cannot be determined whether the AE is treatment emergent due to an incomplete onset date, the AE was considered treatment emergent. Local skin reactions to treatment were recorded as AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. utilized a treatment interval of at least 14 days between treatments with longer treatment intervals being allowed depending on a specific patient's clinical response. No paring of lesions was allowed. Subjects were 2 years and older.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator. Utilized a treatment interval of 21 days between treatments. Paring of lesions was allowed. Subjects were 12 years and older.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site vesicles</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <description>Application site pain</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <description>Application site erythema</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <description>Application site pruritus</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Application site scab</sub_title>
                <description>Application site scab</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <description>Application site dryness</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <description>Application site oedema</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Application site discolouration</sub_title>
                <description>Application site discolouration</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Application site exfoliation</sub_title>
                <description>Application site exfoliation</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Application site erosion</sub_title>
                <description>Application site erosion</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <description>Papilloma viral infection</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI is bound to terms and conditions of a Sponsored Clinical Trial Agreement which has strict confidentiality obligations running to Sponsor and broad provisions restricting PI's rights to publish or present any data or Study Results without Sponsor's express review consent and review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Cutler, VP, Medical Affairs</name_or_title>
      <organization>Verrica Pharmaceuticals</organization>
      <phone>484-773-0898</phone>
      <email>scutler@verrica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

